Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Plasma Medicine
SJR: 0.278 SNIP: 0.183 CiteScore™: 0.57

ISSN Druckformat: 1947-5764
ISSN Online: 1947-5772

Plasma Medicine

DOI: 10.1615/PlasmaMed.2014011882
pages 243-265

Promising Trial for Treatment of Chronic Myelogenous Leukemia Using Plasma Technology

M. M. Ahmed
Radiation Biology Department, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt
Gamal M. El-Aragi
Plasma Department, Nuclear Research Center, Egyptian Atomic Energy Authority, Cairo, Egypt
Abdel Monsef A. Elhadary
Biological Application Dept., Nuclear Research center, Atomic Energy Authority Cairo, Egypt
Z. S. Said
Radiation Safety Department, Nuclear & Radiological Regulatory Authority, Cairo, Egypt

ABSTRAKT

This article presents a trial of the treatment of chronic-phase (CP) and accelerated-phase (AP) chronic myelogenous leukemia (CML) that is resistant or only partially responded to chemotherapy. Blood samples of 6 cases diagnosed with CML were studied and compared with a control group. The first 3 cases were AP CML resistant to imatinib and nilotinib. The other 3 partially responded to the chemotherapy and returned to CP CML. Triple blood cultures for each case were exposed to a cold, pulsed, atmospheric pressure plasma jet for different durations (40, 80, and 120 seconds). Hematological, cytogenetic, and biochemical investigations were done before and after plasma jet exposure. The results showed an increase in necrotic and apoptotic cell counts and a decrease in the number of characteristic nucleoplasmic bridges (multinucleated threadlike shape). Concentrations of transforming growth factor-β1 and arginase decreased in the CML blood samples after exposure to plasma jet.This type of nonthermal plasma can kill cancer cells and prevent the cells from dividing, especially for the 80-second duration.


Articles with similar content:

Cytogenetic and Biochemical Investigations of Cultured Leukemia Cells Exposed to Gliding Arc Discharges
Plasma Medicine, Vol.7, 2017, issue 1
A. A. Elhadry, Gamal M. El-Aragi, S. A. Montaser, M. M. Ahmed, Z. S. Said
In Vitro Studies with the Calcimimetic, Cinacalcet HCl, on Normal Human Adult Osteoblastic and Osteoclastic Cells
Critical Reviews™ in Eukaryotic Gene Expression, Vol.13, 2003, issue 2-4
Alana Rattan, Meiying Qi, Brian Varnum, David Martin, Victoria Shalhoub, Jen Padagas, Mario Grisanti, David Lacey, Chris Vezina, Sheila Scully
Anticancer Effect of Fraction Isolated from Medicinal Birch Polypore Mushroom, Piptoporus betulinus (Bull.: Fr.) P. Karst. (Aphyllophoromycetideae): In Vitro Studies
International Journal of Medicinal Mushrooms, Vol.11, 2009, issue 4
Wojciech Rzeski, Jozef Kaczor, Ewa Langner, Bozena Sanecka, Witold Mazurkiewicz, Martyna Kandefer-Szerszen, Marta Kinga Lemieszek
Clinical Significance of YY1 Overexpression in Human Hematopoietic Malignancies
Forum on Immunopathological Diseases and Therapeutics, Vol.1, 2010, issue 1-2
Silvana Canevari, Giancarlo Castellano, Sara Huerta-Yepez, Mario I. Vega, Ma del Lourdes Cabrera-Munoz, Clara M. Rivera Pazos, Loredana Militello, Haiming Chen, Massimo Libra, Stavroula Baritaki, Grazia Malaponte, James R. Berenson
Repeated Cold Atmospheric Plasma Application to Intact Skin Does Not Cause Sensitization in a Standardized Murine Model
Plasma Medicine, Vol.7, 2017, issue 4
Claus-Dieter Heidecke, Julia van der Linde, Kim Rouven Liedtke, Axel Kramer, Lars Ivo Partecke, Rutger Matthes